197 related articles for article (PubMed ID: 23085694)
1. [Myeloproliferative neoplasms: histopathological and molecular pathological diagnosis].
Hussein K; Büsche G; Schlue J; Lehmann U; Kreipe H
Pathologe; 2012 Nov; 33(6):508-17. PubMed ID: 23085694
[TBL] [Abstract][Full Text] [Related]
2. Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics.
Tefferi A; Skoda R; Vardiman JW
Nat Rev Clin Oncol; 2009 Nov; 6(11):627-37. PubMed ID: 19806146
[TBL] [Abstract][Full Text] [Related]
3. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
[TBL] [Abstract][Full Text] [Related]
4. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
5. Phospho-STAT5 expression pattern with the MPL W515L mutation is similar to that seen in chronic myeloproliferative disorders with JAK2 V617F.
Gibson SE; Schade AE; Szpurka H; Bak B; Maciejewski JP; Hsi ED
Hum Pathol; 2008 Jul; 39(7):1111-4. PubMed ID: 18479730
[TBL] [Abstract][Full Text] [Related]
6. The histopathology of chronic myeloproliferative diseases.
Georgii A; Buesche G; Kreft A
Baillieres Clin Haematol; 1998 Dec; 11(4):721-49. PubMed ID: 10640214
[TBL] [Abstract][Full Text] [Related]
7. [Bone marrow biopsy: processing and use of molecular techniques].
Quintanilla-Martinez L; Tinguely M; Bonzheim I; Fend F
Pathologe; 2012 Nov; 33(6):481-9. PubMed ID: 23085692
[TBL] [Abstract][Full Text] [Related]
8. [Chronic myeloid neoplasms. Diagnostic criteria and current therapeutic concepts].
Schmitt-Graeff AH
Pathologe; 2010 Feb; 31(1):29-41. PubMed ID: 20076959
[TBL] [Abstract][Full Text] [Related]
9. T lymphoid/myeloid bilineal crisis in chronic myelogenous leukemia.
Akashi K; Mizuno S; Harada M; Kimura N; Kinjyo M; Shibuya T; Shimoda K; Takeshita M; Okamura S; Matsumoto I
Exp Hematol; 1993 Jun; 21(6):743-8. PubMed ID: 7684698
[TBL] [Abstract][Full Text] [Related]
10. Blast Transformation in Myeloproliferative Neoplasms: Risk Factors, Biological Findings, and Targeted Therapeutic Options.
Iurlo A; Cattaneo D; Gianelli U
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31013941
[TBL] [Abstract][Full Text] [Related]
11. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
Hussein K; Bock O; Theophile K; von Neuhoff N; Buhr T; Schlué J; Büsche G; Kreipe H
Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600
[TBL] [Abstract][Full Text] [Related]
12. [Diagnostic molecular pathology of lymphatic and myeloid neoplasms].
Klapper W; Kreipe H
Pathologe; 2015 Mar; 36(2):164-70. PubMed ID: 25809654
[TBL] [Abstract][Full Text] [Related]
13. Chronic myeloproliferative disorders: a tyrosine kinase tale.
De Keersmaecker K; Cools J
Leukemia; 2006 Feb; 20(2):200-5. PubMed ID: 16341034
[TBL] [Abstract][Full Text] [Related]
14. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
15. Targeting Abnormal Hematopoietic Stem Cells in Chronic Myeloid Leukemia and Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms.
Yung Y; Lee E; Chu HT; Yip PK; Gill H
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33440869
[TBL] [Abstract][Full Text] [Related]
16. [Analysis of CALR, JAK2 and MPL gene mutations in BCR-ABL negative myeloproliferative neoplasms].
Ouyang Y; Qiao C; Wang J; Xiao L; Zhang S
Zhonghua Yi Xue Za Zhi; 2015 May; 95(18):1369-73. PubMed ID: 26178351
[TBL] [Abstract][Full Text] [Related]
17. [Bone marrow diagnostics: integrative evaluation of results is a duty].
Fend F
Pathologe; 2012 Nov; 33(6):479-80. PubMed ID: 23085691
[No Abstract] [Full Text] [Related]
18. Clonal evolution of AML1-ETO coexisting with BCR-ABL and additional chromosome abnormalities in a blastic transformation of chronic myeloid leukemia.
Ma CC; Chai Y; Chen HL; Wang X; Gao Y; Hu WL; Xiang X
J Int Med Res; 2020 May; 48(5):300060520919237. PubMed ID: 32366154
[TBL] [Abstract][Full Text] [Related]
19. Molecular pathogenesis of chronic myeloid leukemia: implications for new therapeutic strategies.
Warmuth M; Danhauser-Riedl S; Hallek M
Ann Hematol; 1999 Feb; 78(2):49-64. PubMed ID: 10089019
[TBL] [Abstract][Full Text] [Related]
20. The role of beta-catenin in chronic myeloproliferative disorders.
Jauregui MP; Sanchez SR; Ewton AA; Rice L; Perkins SL; Dunphy CH; Chang CC
Hum Pathol; 2008 Oct; 39(10):1454-8. PubMed ID: 18619646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
